References
- ChenWZhengRZengHZhangSEpidemiology of lung cancer in ChinaThorac Cancer20156220921526273360
- ShiYSunYDingCChina experts consensus on icotinib for non-small cell lung cancer treatment (2015 version)Ann Transl Med201531826026605306
- ChenYHanSZhengMJXueYLiuWCClinical characteristics of 274 non-small cell lung cancer patients in ChinaOnkologie201336524825423689218
- CiuleanuTBrodowiczTZielinskiCMaintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 studyLancet20093741432144019767093
- FidiasPMDakhilSRLyssAPPhase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancerJ Clin Oncol20092759159819075278
- CappuzzoFCiuleanuTStelmakhLErlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 studyLancet Oncol20101152152920493771
- BrodowiczTKrzakowskiMZwitterMCisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase III trialLung Cancer20065215516316569462
- PérolMChouaidCPérolDRandomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancerJ Clin Oncol2012303516352422949150
- ChattopadhyaySMoranRGGoldmanIDPemetrexed: biochemical and cellular pharmacology, mechanisms, and clinical applicationsMol Cancer Ther20076240441717308042
- Alimta (pemetrexed) [prescribing information]Indianapolis, INEli Lilly and Company2015
- ShiYSunYMedical management of lung cancer: experience in ChinaThorac Cancer201561101626273329
- GoldMSeigelJRussellLWeinsteinMCost-Effectiveness in Health and MedicineOxford, UKOxford University Press1996
- EdejerT-TBaltussenRAdamTWHO Guide to Cost-Effectiveness AnalysisGeneva, SwitzerlandWorld Health Organization2003
- Central Intelligence AgencyWorld FactbookChinaGDP Per Capita (PPP)2014 Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/ch.htmlAccessed October 17, 2016
- Google FinanceFX Rate Available from: https://www.google.com/finance?q=USDCNY&ei=QAWOV_mrDsWy2AaTvqL4DgAccessed February 9, 2016
- Paz-AresLde MarinisFDediuMMaintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trialLancet Oncol20121324725522341744
- Paz-AresLGde MarinisFDediuMPARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancerJ Clin Oncol201331232895290223835707
- GlasziouPPSimesRJGelberRDQuality adjusted survival analysisStat Med1990911125912762277877
- HoyleMWHenleyWImproved curve fits to summary survival data: application to economic evaluation of health technologiesBMC Med Res Methodol20111113921985358
- NafeesBStaffordMBhallaSWatkinsJHealth utilities in the UK for second line non-small cell lung cancerValue Health20069A296
- ZengXPengLLiJChenGCost-effectiveness of continuation maintenance pemetrexed after cisplatin and pemetrexed chemotherapy for advanced nonsquamous non-small-cell lung cancer: estimates from the perspective of the Chinese health care systemClin Ther2013351546523328269
- LeeSGJeeYGChungHCCost-effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluororacil, doxorubicin and cyclophosphamide (FAC)Breast Cancer Res Treat200911458959518437555
- GBIHealthMax Retail PricingGB Group Limited Available from: http://source.gbihealth.com/Pricing/MaxRetailPricingAccessed October 19, 2016
- LiubaoPXiaominWChongqingTCost-effectiveness analysis of adjuvant therapy for operable breast cancer from a Chinese perspective: doxorubicin plus cyclophosphamide versus docetaxel plus cyclophosphamidePharmacoeconomics20092787388619803541